Thymos Health
Your Alopecia Areata Journey

Still losing hair.
Still cycling through steroid injections.
Still not sure it will last.

You're not alone. This is how alopecia areata is typically managed — and an honest look at what that journey costs, and what it leads to, over time.

6.7M Americans will experience alopecia areata during their lifetime.1
2 oral JAK inhibitors are FDA-approved for severe disease, both since 2022.2
~45% of patients reach near-full hair regrowth (SALT ≤20) on the newer JAK inhibitors.3
$50–90K/yr is the list price for the oral JAK inhibitors used in severe alopecia.4

How severe alopecia areata is typically treated

Most dermatologists and insurance plans move from topical/injected steroids, to immunotherapy, before considering the biologic JAK inhibitor.

Mark where you are in your journey and we'll show you the full picture.

Step 1: Your dermatologist starts you with Intralesional / Topical Corticosteroids
Triamcinolone injections every 4–6 weeks, or high-potency topical steroids
What your doctor says
"Let's start with steroid injections directly into the bald patches. This is the standard first-line approach for patchy alopecia areata."
Can be effective for limited, patchy disease
Regrowth is often not durable once injections stop
Limited effect on extensive scalp or body-wide hair loss
Annual cost before insurance ~$800–$2,500
Providers seen before this was prescribed
How long were you on this?
What happened?
Your coinsurance for this drug
Your estimated annual out-of-pocket for this drug
$0
Extensive or recurrent hair loss — contact immunotherapy considered
Step 2: For more extensive disease, you try Contact Immunotherapy
Diphenylcyclopropenone (DPCP) — induces a controlled allergic scalp reaction weekly, in-office
What your doctor says
"For more extensive patches, we can try contact immunotherapy. It works by deliberately triggering a mild allergic reaction on your scalp to redirect the immune response."
Long track record for moderate-to-extensive disease
Requires weekly in-office visits for months
Response is unpredictable and often partial
Annual cost before insurance ~$2,000–$6,000
How long were you on this?
What happened?
Your coinsurance for this drug
Your estimated annual out-of-pocket for this drug
$0
Severe / refractory disease (>50% scalp hair loss) — oral JAK inhibitor considered
Step 3: For severe disease, you're approved for Oral JAK Inhibitor
Ritlecitinib (Litfulo) or baricitinib (Olumiant) — once-daily pill, FDA-approved since 2022
What your doctor says
"Since your hair loss is severe, we can now try an oral JAK inhibitor. This is the first pill ever specifically approved for alopecia areata."
45% of patients reach near-full hair regrowth (SALT ≤20) by week 52 on ritlecitinib3
~29% are non-responders even after a full year3
Response typically requires 6–12+ months to assess fully5
Annual list price before insurance ~$49,000–$89,000
How long were you on this?
What happened?
Your coinsurance for this drug
Your estimated annual out-of-pocket for this drug
$0
When alopecia areata outlasts (or outprices) treatment, Hair Loss After Discontinuation is Common
Regrowth that depends on continuous, expensive therapy — with no cure and a high relapse rate off treatment
What Your Doctor says
"Your hair has regrown nicely on the medication. If cost or side effects become an issue and you need to stop, we'd expect the hair loss to likely return."
Response requires ongoing daily therapy — this is not a cure
~29% of patients remain non-responders even after a year3
Real-world discontinuation rates for JAK inhibitors run 30–70% by year 1–46
45.5%
Of patients reach near-full hair regrowth (SALT ≤20) by week 52 on ritlecitinib7
29.3%
Are non-responders despite treatment7
93.1%
Of responders sustain their response if treatment continues7
$49–89K/yr
Annual list price range for the drugs required to sustain regrowth4
Response categories at 24 months (ALLEGRO ritlecitinib program)
Responders (SALT ≤20, sustained) 45.5%
Partial responders 12.6%
Relapsers (achieved but lost response) 12.6%
Non-responders 29.3%
What durability actually requires
⏳ Full response can take over a year to emerge. Up to 11% of eventual responders needed more than 12 months of continuous ritlecitinib therapy to reach SALT ≤20 — meaning insurers and patients often have to commit to a full year of drug spend before knowing whether it's working.7
💊 This is maintenance therapy, not a cure. There is no evidence that stopping a JAK inhibitor after successful regrowth preserves that regrowth — the disease is expected to recur once the drug is withdrawn, since the underlying autoimmune process isn't resolved.
💰 Cost-per-responder is a real, calculated metric — because so many patients don't respond. Formal cost-per-responder models comparing ritlecitinib and baricitinib exist specifically because a meaningful share of patients on each drug never reach a meaningful response, making the effective cost per successful outcome much higher than the list price alone.8
🧠 The psychosocial burden is why patients push through years of this ladder. Patient experts describe severe alopecia areata as having a “profound impact on psychosocial health” — which is precisely why so many patients tolerate years of injections, immunotherapy, and expensive pills in pursuit of regrowth.9
⚠ “Approved” doesn't mean “guaranteed” — or “affordable”
Alopecia areata now has real, FDA-approved options for the first time — a major advance. But close to a third of patients on the newest therapy still don't respond, and the drugs that do work must generally be taken indefinitely at list prices in the tens of thousands of dollars a year.

What alopecia areata is really costing you

The drug cost is only part of it. Years of injections, immunotherapy visits, wigs, and the psychosocial burden of visible hair loss all carry a real financial and emotional cost most calculators ignore.

Based on your journey above–adjust the numbers to match your situation.
Work/social days affected by hair loss or treatment visits in the last 12 months
Your hourly wage (for lost income calculation)
Your estimated total annual cost of alopecia areata $0
Drug out-of-pocket costs $0
Lost income (missed days) $0
Reduced productivity at work (presenteeism) $0
Weekly in-office immunotherapy visits and the psychosocial burden of visible hair loss both carry real time and productivity costs
If your care reaches the last phase of this journey — Oral JAK Inhibitor
$0
Projected patient out-of-pocket for a full year on oral JAK Inhibitor, given your coinsurance selection for it above (or a typical default if you haven't reached it yet)

What your insurer is paying

Alopecia areata went from essentially no approved systemic drug spend to a $50,000–$90,000/year specialty pharmacy category almost overnight, once the first oral JAK inhibitors were approved in 2022.

Annual Payer Perspective — Commercial Insurance
What your health plan spends on your alopecia areata each year
Mark your journey above to calculate your cost · All figures reflect the payer (insurer) paid portion, not your out-of-pocket cost.
Estimated annual payer cost for your alopecia areata care $0
JAK inhibitor / immunotherapy drug spend (payer portion)
~80% of list price after patient coinsurance; oral JAK inhibitors are the newest and by far the largest cost driver in alopecia areata
$0
Medical costs (dermatology visits, injections, monitoring labs)
JAK inhibitors require baseline and ongoing lab monitoring (CBC, lipids, liver function)
~$1,800
Have you had to switch therapies due to non-response?
A switch effectively restarts the cost-per-responder clock on a second $50,000+/year drug
Oral JAK inhibitors for severe alopecia areata list at $49,000–$89,000/year — a completely new specialty-pharmacy cost category created since 2022.
Payer cost projection if care reaches the last phase of this journey — Oral JAK Inhibitor
$0
Estimated annual payer spend at that phase: ~80% of drug price plus baseline medical costs, excluding any flare/crisis event above
⚑ Why cost-per-responder, not list price, is the real number
Because roughly 3 in 10 patients don't respond even after a year of therapy, formal cost-per-responder analyses run substantially higher than the sticker price suggests — a detail that matters enormously for a drug class with no generic alternative and no cure to fall back on.
Understanding Your Risk

What the research shows over time

These outcomes are not inevitable — but they are the documented range of what today's best available therapies can and cannot deliver for severe alopecia areata.

Based on peer-reviewed clinical data
Long-term outcomes for alopecia areata patients on today's standard of care
💊
45.5% of patients on the newer JAK inhibitor reach SALT ≤20 (near-full regrowth) with sustained response through 24 months7
🚫
29.3% remain non-responders despite a full course of modern oral JAK inhibitor therapy7
🔁
12.6% achieve response but relapse — regrowth is not guaranteed to be durable even while remaining on treatment7
💰
$49–89K/yr list price required to sustain regrowth indefinitely, since stopping treatment is expected to allow hair loss to return4
✦ A different journey exists

Thymos Health offers another way

Conventional alopecia areata care focuses on managing symptoms through sequential medications. Thymos goes further – synthesizing diagnostics, medical history, symptoms, and lifestyle to understand what's driving your disease and customizes care based on your individual needs.

✓
Root cause treatment — not just another layer of suppression
✓
Whole system autoimmune specialist quarterbacks your labs, your team, your care plan
✓
24/7 personalized support — not just at your next follow-up in 3 months
✓
80%+ symptom relief within 3 months across autoimmune conditions
No commitment. Takes 2 minutes.
Sources & Citations ▼
[1] National Alopecia Areata Foundation prevalence estimates, cross-referenced with FDA drug-approval program materials; commonly cited range of 700,000 to 2 million Americans with active alopecia areata at any given time.
Source: FDA/VA formulary monograph
[2] Ritlecitinib (LITFULO) in Alopecia Areata National Drug Monograph, U.S. Department of Veterans Affairs, 2023. Ritlecitinib and baricitinib are the two FDA-approved oral JAK inhibitors for severe alopecia areata, both approved since 2022.
Source: va.gov
[3] Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme. PMC, 2025. Of 191 patients treated with ritlecitinib 50mg: 45.5% were SALT ≤20 responders, 12.6% partial responders, 12.6% relapsers, 29.3% non-responders through Month 24.
PMC: PMC12105426
[4] A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata. Journal of Health Economics and Outcomes Research, 2026. Cost modeling based on U.S. wholesale acquisition costs for once-daily ritlecitinib 50mg and baricitinib 2mg/4mg over a 1-year time horizon.
DOI: 10.36469/001c.159914
[5] Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata (ALLEGRO-LT). PMC, 2025. At Month 24, 73.5% and 66.4% of patients achieved SALT ≤20 and ≤10 respectively; mean exposure was 728.7 days, indicating extended treatment duration is typical.
PMC: PMC12105460
[6] Cost-Effectiveness Analysis of Ritlecitinib Compared With No Treatment in Patients With Severe Alopecia Areata in Japan. PMC, 2025. Real-world JAK inhibitor discontinuation/retention benchmarks cited from rheumatoid arthritis literature: ~50% retention at 4 years (Spain), ~70% discontinuation within 12 months in some Japanese cohorts, primarily due to non-response.
PMC: PMC13075529
[7] Same ALLEGRO patterns-of-response study (PMC12105426): full response-category breakdown through Month 24, including sustained response and complete response rates among responders.
PMC: PMC12105426
[8] A Cost Per Responder Analysis of Ritlecitinib and Baricitinib, ISPOR 2025 poster. Decision-tree cost modeling explicitly built around the fact that a substantial share of initiators on either drug do not reach a meaningful SALT response, making cost-per-responder a materially different (and higher) figure than list price alone.
Source: ispor.org
[9] Ritlecitinib for treating severe alopecia areata in people 12 years and over. NICE/NCBI Bookshelf technology appraisal, 2024. Patient experts described living with severe alopecia areata as having “a profound impact on psychosocial health.”
Source: NCBI Bookshelf